Tagrisso

Basic Information

• Category: pharmaceutical product
• Website: https://www.tagrisso.com/

Documented Facts

• Phone: 1-800-236-9933 (No linked source recorded for this statement.)

Evidence and Sources

• Tagrisso — Official Site (official)
• Tagrisso on facebook (social)

Citation Guidance

Explore pharmaceutical product profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Tagrisso.

• Canonical profile: https://brandsource.ai/brands/tagrisso
• Machine-readable JSON-LD: https://brandsource.ai/api/brands/tagrisso/json-ld
• Citation profile API: https://brandsource.ai/api/brands/tagrisso/citation-profile
• Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
• Data status: Partial
• Profile completeness: Source-backed profile (76/100)
• Indexing directive: index, follow, max-image-preview:large
• Recorded profile date: 2026-04-21

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Learn how TAGRISSO® (osimertinib) supports patients at different stages of EGFR+ NSCLC. Talk to your doctor to see if TAGRISSO is right for you.

Available profile information

• Official website is captured for entity disambiguation.
• 1 official source linked for verification.
• 1 supporting source linked.
• 1 structured fact available for extraction.

Known data gaps

• Profile enrichment is incomplete

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.